Cover Image
市場調查報告書

困難梭狀芽孢桿菌傳染病 :開發中產品分析

Clostridium difficile Infections - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 255954
出版日期 內容資訊 英文 188 Pages
訂單完成後即時交付
價格
Back to Top
困難梭狀芽孢桿菌傳染病 :開發中產品分析 Clostridium difficile Infections - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 188 Pages
簡介

困難梭狀芽孢桿菌傳染病是因稱作困難梭狀芽孢桿菌的細菌被引起的感染疾病,會引起從腹瀉到結腸的致命性感染等廣泛的症狀。症狀有腹痛和伴隨壓痛的水狀腹瀉,食慾衰退,發燒,混雜血和膿的糞便,體重減輕等。危險因素有年齡,消化管手術,免疫力低,腎臟病,降低胃酸用質子幫浦抑制劑及使用化療藥等。這些症狀可藉由管理抗生素類藥物的使用、改正生活習慣來加以預防。

本報告提供全球各國治療困難梭狀芽孢桿菌傳染病 (困難梭狀芽孢桿菌相關疾病) 所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

困難梭狀芽孢桿菌傳染病 (困難梭狀芽孢桿菌相關疾病)的概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發中產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

困難梭狀芽孢桿菌傳染病 (困難梭狀芽孢桿菌相關疾病):治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

困難梭狀芽孢桿菌傳染病 (困難梭狀芽孢桿菌相關疾病)的治療藥開發企業

  • Absynth Biologics Ltd
  • Actelion Ltd
  • AIMM Therapeutics BV
  • Akthelia Pharmaceuticals Ltd
  • AmpliPhi Biosciences Corp
  • Appili Therapeutics
  • Assembly Biosciences Inc
  • AvidBiotics Corp
  • C3J Therapeutics Inc
  • CaroGen Corp
  • Crestone Inc
  • Da Volterra SAS
  • 第一三共
  • Evec Inc
  • GangaGen Inc
  • ImmunoBiology Ltd
  • Immuron Ltd
  • Inovio Pharmaceuticals Inc
  • Integrated BioTherapeutics Inc
  • Merck & Co Inc
  • MGB Biopharma Ltd
  • Microbiotix Inc
  • Micropharm Ltd
  • Miyarisan Pharmaceutical Company Ltd
  • Nabriva Therapeutics AG
  • Nanotherapeutics Inc
  • Novabiotics Ltd
  • NovoBiotic Pharmaceuticals LLC
  • Oragenics Inc
  • Otsuka Holdings Co Ltd
  • Pfizer Inc
  • Prokarium Ltd
  • Rebiotix Inc
  • Sanofi Pasteur SA
  • Second Genome Inc
  • Seres Therapeutics Inc
  • Serometrix LLC
  • Sorrento Therapeutics Inc
  • Summit Therapeutics Plc
  • Synthetic Biologics Inc
  • Valevia UK Ltd
  • Valneva SE
  • XBiotech Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9252IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 11, 29, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview
    • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
    • Absynth Biologics Ltd
    • Actelion Ltd
    • AIMM Therapeutics BV
    • Akthelia Pharmaceuticals Ltd
    • AmpliPhi Biosciences Corp
    • Appili Therapeutics
    • Assembly Biosciences Inc
    • AvidBiotics Corp
    • C3J Therapeutics Inc
    • CaroGen Corp
    • Crestone Inc
    • Da Volterra SAS
    • Daiichi Sankyo Company Ltd
    • Evec Inc
    • GangaGen Inc
    • ImmunoBiology Ltd
    • Immuron Ltd
    • Inovio Pharmaceuticals Inc
    • Integrated BioTherapeutics Inc
    • Merck & Co Inc
    • MGB Biopharma Ltd
    • Microbiotix Inc
    • Micropharm Ltd
    • Miyarisan Pharmaceutical Company Ltd
    • Nabriva Therapeutics AG
    • Nanotherapeutics Inc
    • Novabiotics Ltd
    • NovoBiotic Pharmaceuticals LLC
    • Oragenics Inc
    • Otsuka Holdings Co Ltd
    • Pfizer Inc
    • Prokarium Ltd
    • Rebiotix Inc
    • Sanofi Pasteur SA
    • Second Genome Inc
    • Seres Therapeutics Inc
    • Serometrix LLC
    • Sorrento Therapeutics Inc
    • Summit Therapeutics Plc
    • Synthetic Biologics Inc
    • Valevia UK Ltd
    • Valneva SE
    • XBiotech Inc
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
    • ABCD-01 - Drug Profile
    • ABIM-101 - Drug Profile
    • AKT-10081 - Drug Profile
    • Antibodies for Enterocolitis - Drug Profile
    • Antibodies to Inhibit Toxin A and Toxin B for Clostridium difficile Infections - Drug Profile
    • AvR2-V10 - Drug Profile
    • Biologic for Clostridium difficile Infections - Drug Profile
    • Biologics for Clostridium Difficile Infections - Drug Profile
    • cadazolid - Drug Profile
    • CBM-588 - Drug Profile
    • CD-17DL - Drug Profile
    • Cdiff Snare - Drug Profile
    • clofazimine - Drug Profile
    • Clostridium difficile (virus like particle) vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • CP-101 - Drug Profile
    • CRS-3123 - Drug Profile
    • DAV-132 - Drug Profile
    • DiffiKil - Drug Profile
    • Drugs for Clostridium difficile Infections - Drug Profile
    • DS-2969 - Drug Profile
    • EV-029104 - Drug Profile
    • EV-029105A - Drug Profile
    • fidaxomicin - Drug Profile
    • FIN-403 - Drug Profile
    • IMM-529 - Drug Profile
    • INS-5010 - Drug Profile
    • MBX-500 - Drug Profile
    • MCB-3681 - Drug Profile
    • MCB-3837 - Drug Profile
    • metronidazole - Drug Profile
    • MGBBP-3 - Drug Profile
    • Monoclonal Antibodies for Clostridium difficile Infections - Drug Profile
    • Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections - Drug Profile
    • Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile
    • Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile
    • Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
    • NP-432 - Drug Profile
    • OG-253 - Drug Profile
    • OG-716 - Drug Profile
    • OPS-2071 - Drug Profile
    • OraCAb - Drug Profile
    • P-100031 - Drug Profile
    • P-4A - Drug Profile
    • PF-06425090 - Drug Profile
    • PolyCAb - Drug Profile
    • Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile
    • ramoplanin - Drug Profile
    • RBX-2660 - Drug Profile
    • RBX-7455 - Drug Profile
    • ribaxamase - Drug Profile
    • ridinilazole - Drug Profile
    • SER-109 - Drug Profile
    • SER-262 - Drug Profile
    • SHP-01 - Drug Profile
    • Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile
    • Small Molecules for Clostridium Difficile Infections - Drug Profile
    • Small Molecules for Clostridium Difficile Infections - Drug Profile
    • Small Molecules for Clostridium difficile Infections - Drug Profile
    • Small Molecules to Inhibit 23S rRNA for Clostridium difficile and Helicobacter pylori Infections - Drug Profile
    • Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
    • Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile
    • Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile
    • Small Molecules to Inhibit Metalloprotease for Clostridium difficile Infections - Drug Profile
    • Small Molecules to Inhibit Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
    • SQ-641 - Drug Profile
    • SYN-006 - Drug Profile
    • SYN-007 - Drug Profile
    • TNP-2092 - Drug Profile
    • VAL-301 - Drug Profile
    • VE-303 - Drug Profile
    • VLA-84 - Drug Profile
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics BV, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corp, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3J Therapeutics Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corp, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra SAS, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nabriva Therapeutics AG, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Serometrix LLC, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Ltd, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top